[iito] Business Intelligence’s Post

Antag Therapeutics Announces €80m Series A Financing Led by Versant Ventures https://lnkd.in/eNPGa7ZM Antag Therapeutics Alexander Sparre-Ulrich Versant Ventures Alexander Mayweg Novo Holdings Jeroen Bakker SR One Capital Management Dawn Biopharma Pictet Group More European life science business news at [LSE] Life-Sciences-Europe.com __

BGV (BioGeneration Ventures) portfolio company Confo Therapeutics, a clinical-stage company and leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the closing of a EUR 60M Series B financing. The round was led by Ackermans & van Haaren (AvH) and included participation from additional new investors, Driehaus Capital Management LLC and Quest for Growth (QfG), as well as existing investors, BGV (BioGeneration Ventures), CAPRICORN HEALTH-TECH FUND (CHF), Fund+, MINTS (University of Michigan), Perceptive Advisors, Qbic Fund | Venture Capital, PMV, V-Bio Ventures, VIB and Wellington Partners. The proceeds will be used to advance two, wholly owned programs through Phase 1 and two additional programs to IND approval, including molecules targeting GPR75 for obesity. Confo will expand its portfolio of GPCR-targeting small molecules and therapeutic antibodies, which includes an emphasis on agonistic antibodies. #seriesB #financing #lifesciences #biotech Edward Van Wezel Diede Brunen

💹💱 It's that time of the week again, Financial Fridays is back with another substantial round of investments. 🥂 As we approach the end of Q1, it's good to see the trend is continuing, and the real positive is the consistency of 9 figure investment rounds, showing how much investors have confidence in the Biotech market. Below is an overview of some of the biggest deals this 💰 Mirador Therapeutics - $400 million launch 💲 Capstan Therapeutics - $175 million oversubscribed series B 💳 Engrail Therapeutics - $157 million series B 💵 Clasp Therapeutics - $150 million launch 🤑 Zephyr AI - $111 million series A #biotechinvestment #venturecapitalist #vcinvestment #financialfridays

Thoughts on this? >> ARCH, biotech's star slugger, snags another $3B for 13th fund >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #healthcare #pharma #biotech

Thoughts on this? >> ARCH, biotech's star slugger, snags another $3B for 13th fund >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #healthcare #biotech

Leading Through Biotech's Perfect Storm: Lessons From The Front Lines https://lnkd.in/e2AA58mn - By Erik van den Berg, CEO, Memo Therapeutics AG

Leading Through Biotech's Perfect Storm: Lessons From The Front Lines https://lnkd.in/e2AA58mn - By Erik van den Berg, CEO, Memo Therapeutics AG

🌴💸 A tropical-themed Financial Friday update for you and I can only apologise for my terrible taste in clothing, luckily the positive investment rounds this week should distract you from that (alternatively just listen to the audio!) A comprehensive overview is in my video but a brief rundown of the funding this week is below: 💰 Zenas BioPharma - $200 million series C 💵 Bluejay Therapeutics - $182 million series C 🤑 Attovia Therapeutics - $105 million series B 💲 Aardvark Therapeutics - $85 million series C 💳 Latus Bio - $54 million launch #financialfriday #biotechinvestment #vcfunding

🎉Congratulations from Checkmate Equity🎉 💼Company: Attovia Therapeutics💰#Funding: $105Million⚡Round: Series B 👥Investors: Goldman Sachs Alternatives, Cormorant Asset Management, LP, Nextech Ventures, Redmile Group, EcoR1 Capital, LLC, Marshall Wace, and Logos Capital. Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated diseases. The company leverages ATTOBODY™, a biparatopic biologics platform, to generate binders that offer stronger efficacy and a broader universe of druggable epitopes compared to traditional approaches. 🚀OFFLOAD YOUR CAP TABLE MANAGEMENT TASKS TODAY🎉 Checkmate Equity is a trusted Carta partner with experience managing over 2,000 #captables. Our expertise ensures compliance, accuracy, and timely updates for your cap table. With a dedicated Equity Administrator, we streamline the process, ensuring rapid updates. 🚀 Tao Fu and Zaneta Odrowaz, let me know if you need assistance with the adjustments to your Cap Table. 📊

Boston is considered by many to be the capital of the #biotech world. But who are the top rising biotechs right now? 🔥 Here are the top 6, ranked by amount raised in the last 2 years: 6. Cellarity: October 2022 - series C - $121 million 5. MOMA Therapeutics: May 2022 - series B - $150 million 4. Orna Therapeutics: August 2022 - series B - $221 million 3. Neumora Therapeutics: October 2022 - series B - $112 million + September 2023 - IPO $250 million 2. Tessera Therapeutics: April 2022 - series C - $300 million 1. ElevateBio: May 2023 - series D - $401 million Labiotech.eu has a list including 6 more companies to watch in the Boston area (link in comments). .................................. #boston #drugdevelopment